Literature DB >> 11841446

Very low frequencies of human normal CD34+ haematopoietic progenitor cells express the Wilms' tumour gene WT1 at levels similar to those in leukaemia cells.

Naoki Hosen1, Yoshiaki Sonoda, Yusuke Oji, Takafumi Kimura, Hitoshi Minamiguchi, Hiroya Tamaki, Manabu Kawakami, Momotaro Asada, Keisuke Kanato, Mari Motomura, Masaki Murakami, Tatsuya Fujioka, Tomoki Masuda, Eui Ho Kim, Akihiro Tsuboi, Yoshihiro Oka, Toshihiro Soma, Hiroyasu Ogawa, Haruo Sugiyama.   

Abstract

The Wilms' tumour gene, WT1, is expressed at high levels in leukaemia cells and plays an important role in leukaemogenesis. WT1 is also expressed in human normal CD34+ bone marrow (BM) cells at about 100 times lower levels than in leukaemia cells. To identify and characterize WT1-expressing cells in CD34+ BM cells, they were sorted into single cells and analysed for WT1 expression using two kinds of single-cell reverse transcriptase polymerase chain reaction (RT-PCR) methods. Using the semiquantitative single-cell polyA-PCR + sequence-specific (SS)-PCR method, WT1 expression was detected in four (1.3%) out of 319 CD34+ BM single cells. To confirm the above results, a single-cell nested sequence-specific (NSS)-RT-PCR method that was less quantitative but more sensitive than the polyA-PCR + SS-PCR method was also performed, and WT1 expression was detected in 15 (1.1%) out of 1315 CD34+ BM single cells. In total, WT1 expression was found in 19 (1.2%) out of 1634 CD34+ BM single cells. No significant differences in the frequencies of WT1-expressing cells were found between CD34+CD38- and CD34+CD38+ BM single cells. Furthermore, WT1-expressing CD34+ BM single cells expressed WT1 at levels similar to those in K562 leukaemia single cells. Analysis of lineage-specific and cell cycle gene expression in WT1-expressing CD34+ BM single cells showed that the WT1 gene could be expressed in both uncommitted, dormant CD34+CD38- and lineage-committed, proliferating CD34+CD38+ BM cells. Our results could indicate that these WT1-expressing CD34+ BM cells were normal counterparts of leukaemia cells.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11841446     DOI: 10.1046/j.1365-2141.2002.03261.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  21 in total

Review 1.  Active specific immunotherapy targeting the Wilms' tumor protein 1 (WT1) for patients with hematological malignancies and solid tumors: lessons from early clinical trials.

Authors:  Ann Van Driessche; Zwi N Berneman; Viggo F I Van Tendeloo
Journal:  Oncologist       Date:  2012-01-30

Review 2.  Evaluation of current cancer immunotherapy: hemato-oncology.

Authors:  Christopher S Hourigan; Hyam I Levitsky
Journal:  Cancer J       Date:  2011 Sep-Oct       Impact factor: 3.360

3.  Prognostic implications of mutations and expression of the Wilms tumor 1 (WT1) gene in adult acute T-lymphoblastic leukemia.

Authors:  Sandra Heesch; Nicola Goekbuget; Andrea Stroux; Jutta Ortiz Tanchez; Cornelia Schlee; Thomas Burmeister; Stefan Schwartz; Olga Blau; Ulrich Keilholz; Antonia Busse; Dieter Hoelzer; Eckhard Thiel; Wolf-Karsten Hofmann; Claudia D Baldus
Journal:  Haematologica       Date:  2010-04-30       Impact factor: 9.941

4.  Mapping of novel peptides of WT-1 and presenting HLA alleles that induce epitope-specific HLA-restricted T cells with cytotoxic activity against WT-1(+) leukemias.

Authors:  Ekaterina Doubrovina; Taissia Carpenter; Dmitry Pankov; Annamalai Selvakumar; Aisha Hasan; Richard J O'Reilly
Journal:  Blood       Date:  2012-05-23       Impact factor: 22.113

5.  Prognostic impact of WT1 expression prior to hematopoietic stem cell transplantation in children with malignant hematological diseases.

Authors:  Caroline Woehlecke; Susan Wittig; Clemens Arndt; Bernd Gruhn
Journal:  J Cancer Res Clin Oncol       Date:  2014-09-20       Impact factor: 4.553

6.  Deficiency in WT1-targeting microRNA-125a leads to myeloid malignancies and urogenital abnormalities.

Authors:  N Tatsumi; N Hojo; O Yamada; M Ogawa; Y Katsura; S Kawata; E Morii; H Sakamoto; R Inaba; A Tsuda; I Fukuda; N Moriguchi; H Hasuwa; M Okabe; F Fujiki; S Nishida; H Nakajima; A Tsuboi; Y Oka; N Hosen; H Sugiyama; Y Oji
Journal:  Oncogene       Date:  2015-05-11       Impact factor: 9.867

Review 7.  Significance of oncogenes and tumor suppressor genes in AML prognosis.

Authors:  Maria Kavianpour; Ahmad Ahmadzadeh; Saeid Shahrabi; Najmaldin Saki
Journal:  Tumour Biol       Date:  2016-05-14

8.  Tumor-associated antigens in breast cancer.

Authors:  Carmen Criscitiello
Journal:  Breast Care (Basel)       Date:  2012-08       Impact factor: 2.860

9.  The lck promoter-driven expression of the Wilms tumor gene WT1 blocks intrathymic differentiation of T-lineage cells.

Authors:  Hanfen Li; Yoshihiro Oka; Akihiro Tsuboi; Tamotsu Yamagami; Toru Miyazaki; Sei-ichi Yusa; Kotomi Kawasaki; Yukiko Kishimoto; Momotaro Asada; Hiroko Nakajima; Keisuke Kanato; Sumiyuki Nishida; Tomoki Masuda; Masaki Murakami; Naoki Hosen; Manabu Kawakami; Hiroyasu Ogawa; Fritz Melchers; Ichiro Kawase; Yusuke Oji; Haruo Sugiyama
Journal:  Int J Hematol       Date:  2003-06       Impact factor: 2.490

10.  Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression.

Authors:  Yoshihiro Oka; Akihiro Tsuboi; Tetsuya Taguchi; Tadashi Osaki; Taiichi Kyo; Hiroko Nakajima; Olga A Elisseeva; Yusuke Oji; Manabu Kawakami; Kazuhiro Ikegame; Naoki Hosen; Satoshi Yoshihara; Fei Wu; Fumihiro Fujiki; Masaki Murakami; Tomoki Masuda; Sumiyuki Nishida; Toshiaki Shirakata; Shin-Ichi Nakatsuka; Ayako Sasaki; Keiko Udaka; Hiroo Dohy; Katsuyuki Aozasa; Shinzaburo Noguchi; Ichiro Kawase; Haruo Sugiyama
Journal:  Proc Natl Acad Sci U S A       Date:  2004-09-13       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.